ACR 2021

New treatment alternative in GCA: promising secukinumab data

axPsA is axSpA is not...!?

ARIAA: prevention study or very early treatment of RA?

Dear Doctor: JAKi risk factors and safety profile - is there a class-effect?

IL-17 pathway important for pain in PsA

No need for methotrexate in ustekinumab treatment in PsA

Pulmonary involvement and possible therapy concepts in RA

Should we use ultra-low-dose rituximab during the pandemic?

Discordance between patients and physicians in RA

Cardiovascular disease in RA

Long awaited - MACE data from ORAL surveillance

Abatacept may reduce subclinical inflammation in RA-at risk patients

Tofacitinib is associated with a slightly increased risk of cancer

We need predictors of response for RA treatment

Cycling JAKi compared to switching to biologic DMARD in patients with RA

Statins reduce cardiovascular risk and​ mortality - with a slight increase in type 2 diabetes risk

Nausea & alopecia with MTX in RA

Quels effets indésirables peuvent être associés à la prise de MTX ?

Désaccords patient/Médecin : se comprendre pour plus d'efficacité

Abatacept reduce la inflamación subclínica en pacientes con artralgia con riesgo de progresión a artritis reumatoide

Quels marqueurs de réponse aux traitements dans la vraie vie ?

Lange erwartet - MACE-Daten zur ORAL Surveillance

Skifte mellom JAK hemmere sammenliknet med skifte til biologisk DMARD hos pasienter med RA

Las estatinas reducen el riesgo cardiovascular y la mortalidad, con un ligero aumento en el riesgo de diabetes tipo 2

Tofacitinid se asocia con un ligero incremento del riesgo de cáncer​

Comparison of composit indices for disease activity in PsA patients

Tildrakizumab in PsA

Joint effusions and enthesitis after physical exertion

Association of C-reactive protein and non-steroidal anti-inflammatory drugs with cardiovascular events

Upadacitinib in PsA

Axial PsA MRI data

Guselkumab: the better ustekinumab?!

No need for MTX in ustekinumab-treated patients

Pain differs: Superior effect of IL-17-inhibition vs. TNF in PsA patients with uncontrolled inflammation

PET/CT in diagnosis for PsA

Secukinumab vs TNF-α blockers in enthesitis

Osteoporosis in PsA

Anemia is an issue in PsA - proper treatment possible!

Prediction of psoriatic arthritis in patients with psoriasis using DNA methylation profiles

Guselkumab in axial symptoms

Kein Hinweis auf Vorteil einer MTX-Kombi zu Ustekinumab

Secukinumab vs TNF-α Blocker bei Enthesitis

Anämie bei PsA ist ein Thema - effektive Therapie möglich!

Tildrakizumab bei PsA

Guselkumab bei axialer Symptomatik

Previsione di sviluppo di artrite psoriasica in pazienti con psoriasi utilizzando profili di metilazione del DNA

Upadacitinib bei PsA

Guselkumab: das bessere Ustekinumab?!

Studio di confronto tra i vari indici compositi per la valutazione di attività di malattia nell'Artrite Psoriasica

PET-CT zur Quantifizierung der Entzündung

Schmerz ist nicht gleich Schmerz: Unterschied von IL-17- und TNF-Inhibition

Osteoporose bei PsA

Datos de RM en APs axial

Gelenkergüsse und Enthesitis nach körperlicher Belastung

Associazione di livelli di PCR e uso di FANS con gli eventi cardiovascolari

Dose tapering of TNF inhibitors in axSpA

JAK inhibitors - new kids on the block

Self-monitoring of disease activity with a smartphone app is feasible in routine clinical management

Axial PsA MRI data

Optimización de iTNF en EspAax

Inhibidores JAK: nuevas dianas en EspAax

Datos de RM en APs axial

l’auto-monitoraggio di malattia è fattibile nella gestione clinica di routine nei pazienti con Spondiloartrite assiale

Not yet a new standard: belimumab + rituximab

JAKi baricitinib successfully mastered phase II study

Kombination Belimumab und Rituximab noch kein neuer Standard

JAK-Inhibitor Baricitinib in Phase II erfolgreich

A new therapeutic approach for giant cell arteritis?

Baricitinib in relapsing giant cell arteritis

Secukinumab in giant cell arteritis

PET as a predictor of vascular damage in large-vessel vasculits

Neuer Therapieansatz für die Riesenzellarteriitis?

Il ruolo della PET nel predire il danno vascolare nelle vasculiti dei grandi vasi

Baricitinib nell'arterite a cellule giganti recidivante

Secukinumab nell'arterite a cellule giganti

Immune responses to COVID-19 vaccines

Analysis of COVID-19 infection among vaccinated patients with rheumatic disease

TNF blockers reduce the antibody response to RNA vaccination

Booster with which one if there is no seroconversion?

Vaccination against Delta variant worse in patients treated with TNF-alpha blocker

Anticytokine antibodies causing severe microbacterial infection

Should we use ultra-low-dose rituximab during the pandemic?

Breakthrough infections after SARS-CoV2-vaccination - national cohort

Impact of COVID-19 on patients with rheumatic diseases

Breakthrough infections after SARS-CoV2-vaccination - global registry

Schlechtere Neutralisation der Delta-Variante unter TNF-alpha Blockern

Durchbruchsinfektionen nach SARS-CoV2-Impfung - nationale Kohorte

TNF-Blocker reduzieren Antikörperantwort bei RNA-Impfung

Womit boostern bei fehlender Serokonversion?

Immunresponser til COVID-19 vaksiner

Durchbruchsinfektionen nach SARS-CoV2-Impfung - globales Register

Pearls and myths in rheumatology

CBD - an alternative therapy for chronic pain

Skin findings in patients of color with rheumatic disease

Therapeutic drug monitoring - a randomized controlled trial (NOR-DRUM B)

New exciting data - dietary supplements with vitamin D and omega-3 fatty acids

PROs from a real-world study on etanercept biosimilar - 1 year follow-up

Monitorering av legemiddelkonsentrasjoner (Therapeutic drug monitoring, NOR-DRUM B) – en randomiseret kontrollert studie

Neue spannende Daten - Nahrungsergänzung mit Vitamin D und Omega-3-Fettsäuren